4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 24, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	514	257	866	719	705	1,098
Market Cap Growth	70.42%	-70.27%	20.40%	2.03%	-35.79%	-
Enterprise Value	164	-268	562	497	478	1,185
Last Close Price	10.07	5.57	20.26	22.21	21.94	41.45
PS Ratio	4280.41	6959.14	41.80	229.93	39.09	80.68
PB Ratio	1.28	0.50	2.81	3.11	2.21	4.28
P/TBV Ratio	1.39	0.50	2.81	3.11	2.21	4.28
EV/Sales Ratio	1364.04	-	27.10	158.89	26.50	87.05
Debt / Equity Ratio	0.06	0.05	0.05	0.07	0.05	-
Net Debt / Equity Ratio	-0.95	-0.94	-0.92	-0.87	-0.94	-1.08
Net Debt / EBITDA Ratio	1.57	2.63	2.62	1.88	4.28	5.01
Net Debt / FCF Ratio	1.89	3.48	3.62	2.06	3.82	5.33
Asset Turnover	0	0	0.07	0.01	0.06	0.08
Quick Ratio	8.22	14.58	15.21	13.58	15.21	16.62
Current Ratio	8.42	14.92	15.65	14.02	15.69	16.88
Return on Equity (ROE)	-45.38%	-39.31%	-37.41%	-39.06%	-24.79%	-39.59%
Return on Assets (ROA)	-27.64%	-26.08%	-23.45%	-22.35%	-13.89%	-20.44%
Return on Capital Employed (ROCE)	-58.70%	-35.40%	-35.20%	-44.70%	-21.20%	-20.90%
Earnings Yield	-40.72%	-62.48%	-11.64%	-14.94%	-10.11%	-5.16%
FCF Yield	-36.03%	-53.74%	-9.07%	-13.65%	-11.10%	-4.73%
Buyback Yield / Dilution	-10.07%	-37.86%	-20.95%	-16.66%	-331.23%	-25.05%

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q